Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 32, Issue 6, 2014, Pages 883-890

  Bergström, Ulf ^a   Grundtman, Cecilia ^b,c   Lundberg, Ingrid E ^b,c   Jacobsson, Lennart T H ^a   Nilsson, Käth ^a   Turesson, Carl ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adalimumab; Cardiovascular disease; CD31; Endothelial activation; HLA DQ; Interleukin 1 ; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD31 ANTIGEN; HLA DQ ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; METHOTREXATE; PREDNISOLONE; VASCULAR CELL ADHESION MOLECULE 1; ANTIRHEUMATIC AGENT; AUTACOID; IL1A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RISK REDUCTION; SKELETAL MUSCLE; TREATMENT DURATION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BIOPSY; DOWN REGULATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOPSY; DOWN-REGULATION; ENDOTHELIAL CELLS; FEMALE; HLA-DQ ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INTERLEUKIN-1ALPHA; MALE; MIDDLE AGED; MUSCLE, SKELETAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925287226     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. WALLBERG-JONSSON S, OHMAN ML, DAHLQVIST SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-51.
2. TURESSON C, JARENROS A, JACOBSSON LTH: Increased incidence of cardiovascular disease in patients with RA - results from a community based study. Ann Rheum Dis 2004; 63: 952-5.
3. MARADIT-KREMERS H, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Cardiovascular deah in rheumatoid arthritis: a population based study. Arthritis Rheum 2005; 52: 722-32.
4. TURESSON C, McCLELLAND RL, CHRISTIANSON TJ, MATTESON EL: Severe extraarticular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 70-5.
5. TURESSON C, ENGLUND P, JACOBSSON LT et al.: Increased endothelial expression of HLA-DQ and interleukin 1 alpha in extraarticular RA. Results from immunohistochemical studies of skeletal muscle. Rheumatology (Oxford) 2001; 40: 1346-54.
6. TURESSON C: Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Design 2004; 10: 129-43.
7. van SIJL AM, PETERS MJ, KNOL DK et al.: Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011; 40: 389-97.
8. TURESSON C, JACOBSSON L, RYDÉN AHLGREN A, STURFELT G, WOLLMER P, LÄNNE T: Increased stiffness of the abdominal aorta in women with rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 896-901.
9. KEREKES G, SZEKANECZ Z, DÉR H et al.: Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008; 35: 398-406.
10. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 115-7.
11. KLARESKOG L, van der HEIJDE D, de JAGER JP et al.: TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
12. LIPSKY PE, van der HEIJDE DM, St CLAIR EW et al.: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Eng J Med 2000; 343: 1594-602.
13. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
14. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
15. JACOBSSON LT, TURESSON C, GÜLFE A et al.: Low incidence of first cardiovascular event in rheumatoid arthritis patients treated with TNF-blockers. J Rheumatol 2005; 2: 1213-8.
16. BARNABE C, MARTIN BJ, GHALI WA: Systematic review and meta-analysis: Anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 522-9.
17. WESTLAKE SL, COLEBATCH AN, BAIRD J et al.: Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011 Mar; 50: 518-31.
18. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al.: Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associatedwith atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
19. GENRE F, MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R et al.: Antitumour necrosis factor-a therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. Ann Rheum Dis 2013; 72: 1265-7.
20. GONZALEZ-JUANATEY C, LLORCA J, SANCHEZ-ANDRADE A, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA: Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006; 24: 309-12.
21. GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MIRANDA-FILLOY JA et al.: Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm 2012; 2012: 674265.
22. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
23. HENRIKSSON KG: "Semi-open" muscle biopsy technique. A simple outpatient procedure. Acta Neurol Scand 1979; 59: 317-23.
24. ©APOTEK PRODUKTION&LABORATORIER AB: http://www.apl.se/En/Pages/welcome. aspx. Accessed January 13, 2012.
25. ULFGREN A-K, GRUNDTMAN C, BORG K et al.: Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004; 50: 1586-94.
26. van GESTEL AM, PREVOO ML, van 't HOF MA, van RIJSWIJK MH, van de PUTTE LB, VAN RIEL PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
27. HANSSON GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
28. RIDKER PM, HENNEKENS CH, BURING JE, RIFAI N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
29. DESSEIN PH, SOLOMON A, WOODIWISS AJ, NORTON GR, TSANG L, GONZALEZ-GAY MA: Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis. Mediators Inflamm 2013; 2013: 510243.
30. LIBBY P, RIDKER PM, HANSSON GK: Inflammation in atherosclerosis from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
31. SOLOMON DH, KARLSON EW, RIMM EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
32. GONZALEZ-JUANATEY C, TESTA A, GARCIACASTELO A et al.: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003; 114: 647-52.
33. POBER JS: Cytokine mediated activation of vascular endothelium. Am J Pathol 1988; 133: 426-33.
34. VALLBRACHT KB, SCHWIMMBECK PL, B SEEBERG, KUHL U, SCHULTHEISS HP: Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies. J Am Coll Cardiol 2002; 40: 415-20.
35. GRUNDTMAN C, HOLLAN I, FØRRE ÖT, SAATVEDT K, MIKKELSEN K, LUNDBERG IE: Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes. Arthritis Rheum 2010; 62: 667-73.
36. BARKLEY D, ALLARD S, FELDMANN M, MAINI RN: Increased expression of HLA-DQ antigens by interstitial cells and endothelium in the synovial membrane of rheumatoid arthritis patients compared with reactive arthritis patients. Arthritis Rheum 1989; 32: 955-63.
37. VERSCHUEREN PC, VOSKUYL AE, SMEETS TJ, ZWINDERMAN KH, BREEDVELD FC, TAK PP: Increased cellularity and expression of adhesion molecules in muscle biopsy specimen from patients with rheumatoid arthritis with clinical suspicion of vasculitis, but negative routine histology. Ann Rheum Dis 2000; 59: 598-606.
38. BUTLER DM, MAINI RN, FELDMANN M, BRENNAN FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995; 6: 225-30.
39. BRODY JI, PICKERING NJ, CAPUZZI DM, FINK GB, CAN CA, GOMEZ F: Interleukin-1 as a factor in occlusive vascular disease. Am J Clin Pathol 1992; 97: 8-13.
40. FROSTEGÅRD J, ULFGREN AK, NYBERG P et al.: Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophagestimulating cytokines. Atherosclerosis 1999; 145: 33-43.
41. DEJANA E, BREVARIO F, ERROI A et al.: Modulation of endothelial cell functions by different molecular species of interleukin-1. Blood 1987; 69: 695-99.
42. TAYLOR PC: Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford) 2005; 44: 721-28.
43. KEREKES G, SOLTÉSZ P, DÉR H et al.: Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci. 2009; 1173: 814-21.
44. DEL PORTO F, LAGANÀ B, LAI S et al.: Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1111-5.
45. MÄKI-PETÄJÄ KM, WILKINSON IB: Antiinflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des 2009; 15: 290-303.
46. KOENEN P, BARCZYK K, WOLF M, ROTH J: Endothelial cells present an innate resistance to glucocorticoid treatment: implications for therapy of primary vasculitis. Ann Rheum Dis 2012; 71: 729-36.
47. MATTEY DL, BROWNFIELD A, DAWES PT: Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1180-7.
48. SAEVARSDOTTIR S, WEDRÉN S, SEDDIGHZADEH M et al.: Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and TNF inhibitors. Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011; 63: 26-36.